Publication | Closed Access

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

Breast OncologySignaling PathwayMedicineReceptor Tyrosine KinaseBreast Cancer CellsBreast CancerCell BiologyCancer BiologyRadiation OncologyCell SignalingTumor Biology